NLS Current Deferred Revenue vs Accounts Payable Analysis

NLSPW Stock

USD 0.01 0 16.67%

NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Current Deferred Revenue and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Current Deferred Revenue vs Accounts Payable

Current Deferred Revenue vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Current Deferred Revenue account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.

The correlation between NLS Pharmaceutics' Current Deferred Revenue and Accounts Payable is 0.84. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Current Deferred Revenue and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of NLS Pharmaceutics AG are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Current Deferred Revenue i.e., NLS Pharmaceutics' Current Deferred Revenue and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Accounts Payable

An accounting item on the balance sheet that represents NLS Pharmaceutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NLS Pharmaceutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Selling General Administrative is likely to climb to about 7.1 M in 2025, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2025.

NLS Pharmaceutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Net Receivables	Inventory	Short Long Term Debt
Total Assets		-0.3	0.03	-0.03	0.85	-0.76	-0.4	0.01	0.96	-0.24	-0.24	-0.3	0.96	0.14	-0.3	0.27	0.07	0.48	-0.63	0.42	0.99	0.56	0.41	0.14	-0.28	0.42
Short Long Term Debt Total	-0.3		-0.8	-0.81	-0.26	0.83	0.84	-0.84	-0.09	-0.36	-0.33	1.0	-0.09	-0.55	0.99	-0.98	-0.59	-0.81	0.62	0.69	-0.24	0.52	-0.71	-0.62	0.92	-0.82
Other Current Liab	0.03	-0.8		0.91	-0.13	-0.52	-0.84	0.99	-0.17	0.36	0.36	-0.81	-0.17	0.69	-0.82	0.85	0.72	0.84	-0.06	-0.81	-0.02	-0.74	0.76	0.27	-0.81	0.86
Total Current Liabilities	-0.03	-0.81	0.91		-0.27	-0.46	-0.84	0.92	-0.28	0.33	0.33	-0.82	-0.28	0.79	-0.81	0.79	0.83	0.73	-0.19	-0.89	-0.08	-0.84	0.81	0.21	-0.8	0.77
Total Stockholder Equity	0.85	-0.26	-0.13	-0.27		-0.72	-0.16	-0.11	0.91	-0.11	-0.13	-0.26	0.91	-0.23	-0.28	0.27	-0.27	0.31	-0.68	0.49	0.85	0.68	0.06	0.42	-0.21	0.25
Net Debt	-0.76	0.83	-0.52	-0.46	-0.72		0.75	-0.55	-0.63	-0.12	-0.1	0.83	-0.63	-0.36	0.84	-0.82	-0.36	-0.8	0.78	0.19	-0.72	-0.02	-0.63	-0.55	0.76	-0.77
Retained Earnings	-0.4	0.84	-0.84	-0.84	-0.16	0.75		-0.84	-0.19	0.03	0.03	0.84	-0.19	-0.85	0.84	-0.83	-0.85	-0.95	0.41	0.59	-0.38	0.46	-0.96	-0.13	0.74	-0.85
Accounts Payable	0.01	-0.84	0.99	0.92	-0.11	-0.55	-0.84		-0.18	0.39	0.39	-0.85	-0.18	0.66	-0.86	0.89	0.71	0.83	-0.13	-0.84	-0.04	-0.75	0.73	0.35	-0.84	0.86
Cash	0.96	-0.09	-0.17	-0.28	0.91	-0.63	-0.19	-0.18		-0.31	-0.31	-0.09	1.0	-0.08	-0.1	0.09	-0.15	0.31	-0.53	0.62	0.97	0.75	0.18	0.1	-0.08	0.23
Non Current Assets Total	-0.24	-0.36	0.36	0.33	-0.11	-0.12	0.03	0.39	-0.31		1.0	-0.39	-0.31	-0.3	-0.37	0.38	-0.22	-0.04	0.06	-0.48	-0.35	-0.45	-0.18	0.7	-0.62	0.34
Non Currrent Assets Other	-0.24	-0.33	0.36	0.33	-0.13	-0.1	0.03	0.39	-0.31	1.0		-0.36	-0.31	-0.3	-0.34	0.36	-0.22	-0.05	0.1	-0.47	-0.35	-0.45	-0.18	0.67	-0.61	0.34
Long Term Debt	-0.3	1.0	-0.81	-0.82	-0.26	0.83	0.84	-0.85	-0.09	-0.39	-0.36		-0.09	-0.54	1.0	-0.98	-0.58	-0.81	0.6	0.7	-0.24	0.52	-0.71	-0.61	0.94	-0.84
Cash And Short Term Investments	0.96	-0.09	-0.17	-0.28	0.91	-0.63	-0.19	-0.18	1.0	-0.31	-0.31	-0.09		-0.08	-0.1	0.09	-0.15	0.31	-0.53	0.62	0.97	0.75	0.18	0.1	-0.08	0.23
Common Stock Shares Outstanding	0.14	-0.55	0.69	0.79	-0.23	-0.36	-0.85	0.66	-0.08	-0.3	-0.3	-0.54	-0.08		-0.54	0.52	0.99	0.75	-0.18	-0.57	0.15	-0.55	0.94	-0.27	-0.4	0.56
Non Current Liabilities Total	-0.3	0.99	-0.82	-0.81	-0.28	0.84	0.84	-0.86	-0.1	-0.37	-0.34	1.0	-0.1	-0.54		-0.99	-0.57	-0.83	0.59	0.68	-0.24	0.51	-0.71	-0.6	0.92	-0.84
Capital Surpluse	0.27	-0.98	0.85	0.79	0.27	-0.82	-0.83	0.89	0.09	0.38	0.36	-0.98	0.09	0.52	-0.99		0.56	0.85	-0.53	-0.68	0.22	-0.51	0.69	0.6	-0.91	0.87
Other Current Assets	0.07	-0.59	0.72	0.83	-0.27	-0.36	-0.85	0.71	-0.15	-0.22	-0.22	-0.58	-0.15	0.99	-0.57	0.56		0.74	-0.16	-0.65	0.08	-0.62	0.92	-0.23	-0.46	0.61
Other Stockholder Equity	0.48	-0.81	0.84	0.73	0.31	-0.8	-0.95	0.83	0.31	-0.04	-0.05	-0.81	0.31	0.75	-0.83	0.85	0.74		-0.41	-0.47	0.46	-0.33	0.89	0.18	-0.71	0.87
Total Liab	-0.63	0.62	-0.06	-0.19	-0.68	0.78	0.41	-0.13	-0.53	0.06	0.1	0.6	-0.53	-0.18	0.59	-0.53	-0.16	-0.41		-0.01	-0.61	-0.18	-0.37	-0.5	0.43	-0.33
Net Invested Capital	0.42	0.69	-0.81	-0.89	0.49	0.19	0.59	-0.84	0.62	-0.48	-0.47	0.7	0.62	-0.57	0.68	-0.68	-0.65	-0.47	-0.01		0.47	0.97	-0.51	-0.31	0.68	-0.54
Total Current Assets	0.99	-0.24	-0.02	-0.08	0.85	-0.72	-0.38	-0.04	0.97	-0.35	-0.35	-0.24	0.97	0.15	-0.24	0.22	0.08	0.46	-0.61	0.47		0.61	0.4	0.06	-0.19	0.36
Net Working Capital	0.56	0.52	-0.74	-0.84	0.68	-0.02	0.46	-0.75	0.75	-0.45	-0.45	0.52	0.75	-0.55	0.51	-0.51	-0.62	-0.33	-0.18	0.97	0.61		-0.43	-0.14	0.53	-0.41
Common Stock	0.41	-0.71	0.76	0.81	0.06	-0.63	-0.96	0.73	0.18	-0.18	-0.18	-0.71	0.18	0.94	-0.71	0.69	0.92	0.89	-0.37	-0.51	0.4	-0.43		-0.06	-0.6	0.75
Net Receivables	0.14	-0.62	0.27	0.21	0.42	-0.55	-0.13	0.35	0.1	0.7	0.67	-0.61	0.1	-0.27	-0.6	0.6	-0.23	0.18	-0.5	-0.31	0.06	-0.14	-0.06		-0.65	0.31
Inventory	-0.28	0.92	-0.81	-0.8	-0.21	0.76	0.74	-0.84	-0.08	-0.62	-0.61	0.94	-0.08	-0.4	0.92	-0.91	-0.46	-0.71	0.43	0.68	-0.19	0.53	-0.6	-0.65		-0.88
Short Long Term Debt	0.42	-0.82	0.86	0.77	0.25	-0.77	-0.85	0.86	0.23	0.34	0.34	-0.84	0.23	0.56	-0.84	0.87	0.61	0.87	-0.33	-0.54	0.36	-0.41	0.75	0.31	-0.88

Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.2M	5.8M	9.3M	1.8M	2.1M	3.3M
Short Long Term Debt Total	7.1M	842.1K	2.1M	1.6M	1.5M	1.4M
Other Current Liab	1.4M	666.4K	986.4K	1.7M	1.9M	1.0M
Total Current Liabilities	7.2M	2.4M	3.4M	7.9M	9.1M	9.6M
Total Stockholder Equity	(9.0M)	542.4K	3.3M	(8.8M)	(10.2M)	(10.7M)
Net Debt	2.0M	(5.4M)	(8.9M)	736.1K	662.5K	695.6K
Retained Earnings	(29.8M)	(41.7M)	(58.2M)	(70.4M)	(63.3M)	(60.2M)
Accounts Payable	4.0M	1.7M	2.4M	4.6M	5.3M	2.7M
Cash	93.7K	5.4M	8.9M	897.7K	1.0M	980.7K
Non Current Assets Total	1.0M	41.6K	30.2K	23.6K	21.2K	20.2K
Non Currrent Assets Other	946.9K	12.0K	12.1K	16.9K	15.2K	14.4K
Cash And Short Term Investments	93.7K	5.4M	8.9M	897.7K	1.0M	980.7K
Common Stock Shares Outstanding	4.8M	14.7M	19.7M	38.2M	43.9M	46.1M
Liabilities And Stockholders Equity	1.2M	5.8M	9.3M	1.8M	2.1M	3.3M
Non Current Liabilities Total	3.0M	2.8M	2.6M	2.8M	2.5M	3.4M
Other Current Assets	14.4K	292.0K	191.0K	914.7K	1.1M	1.1M
Other Stockholder Equity	20.6M	42.1M	60.9M	61.0M	70.1M	35.5M
Total Liab	10.2M	5.2M	6.0M	10.7M	9.6M	6.6M
Net Invested Capital	(6.9M)	542.4K	3.3M	(7.2M)	(6.5M)	(6.2M)
Total Current Assets	196.7K	5.7M	9.2M	1.8M	2.1M	3.1M
Accumulated Other Comprehensive Income	(19.4K)	(151.7K)	(50.8K)	(158.1K)	(142.3K)	(135.2K)
Net Working Capital	(7.0M)	3.3M	5.9M	(6.1M)	(7.0M)	(6.7M)
Net Receivables	61.2K	38.6K	41.2K	10.7K	9.6K	9.1K
Inventory	(33.6K)	(61.2K)	(38.6K)	(41.2K)	(37.1K)	(39.0K)
Short Term Debt	690.1K	1.8M	2.5B	1.6M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NLS Current Deferred Revenue vs Accounts Payable Analysis

Current Deferred Revenue vs Accounts Payable

Current Deferred Revenue vs Accounts Payable Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Accounts Payable

NLS Pharmaceutics fundamental ratios Correlations

NLS Pharmaceutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NLS Pharmaceutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for NLS Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Non Currrent Assets Other	+ 1.0	Non Current Assets Total
Non Current Liabilities Total	+ 1.0	Long Term Debt
Total Current Assets	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total

Capital Surpluse	- 0.99	Non Current Liabilities Total
Capital Surpluse	- 0.98	Long Term Debt
Capital Surpluse	- 0.98	Short Long Term Debt Total
Common Stock	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Inventory	- 0.91	Capital Surpluse